Bloomberg Law Reports/Antitrust & Trade
The Treatment of Pharmaceutical Life Cycle Management Strategies In the European Commission’s Pharmaceutical Sector Inquiry Final Report: An American Perspective
August 2009
In July, 2009, the European Commission issued its long-awaited Pharmaceutical Sector Inquiry Final Report, which claims to examine “the reasons for observed delays in the entry of generic medicines . . . and the apparent decline in innovation as measured by the number of new medicines coming to the market.” This article addresses the Report’s suggestion that originator companies may be guilty of anticompetitive conduct when they patent, and then promote, Second Generation Products in order to compete against generic competitors – i.e., when they engage in common product life cycle management strategies. The conclusion is that the Report has not uncovered conduct, and the EC has not articulated a theory, that could reasonably support any sort of enforcement or remedial action.
得意分野
Suggested News & Insights
Sidley Represents Clearlake Capital Group in Mirendil’s US$1 Billion FinancingNovember 13, 2026Sidley Represents Mubadala Capital in Its Strategic Minority Investment in LSV AdvisorsNovember 11, 2026Sidley Represents Laza Medical in Its US$160 Million Series B Financing RoundNovember 4, 2026Sidley Adds Competition Litigator Elaine Whiteford in LondonNovember 2, 2026October Antitrust and Competition Bulletin: Top-of-Mind Global Antitrust IssuesOctober 22, 2026Revised EU Product Liability Directive: The Long Read — Scope, Key Changes, and Compliance Implications for Businesses (Part 1)October 21, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory